相关实验视频

Updated: Jan 6, 2026

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

Published on: June 19, 2025

通过血管内磁共振成像对人类动脉样硬化斑块的表征

Eric Larose¹, Yerem Yeghiazarians, Peter Libby

¹Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

|October 6, 2005

概括

静脉内MRI (IVMRI) 可以准确地确定深动脉中的动脉硬性斑块组成和大小. 这种成像技术为人类动脉样硬化提供了更好的理解和潜在的修改策略.

科学领域:

心血管成像 - 心血管成像
生物医学工程生物医学工程
放射学放射学是一门学科.

背景情况:

评估动脉样硬化斑块组成对于了解动脉瘤演变和治疗策略至关重要.
表面MRI仅限于表面动脉,需要更深层血管的先进技术.
血管内核磁共振成像 (IVMRI) 被探索其在人类动脉内表征斑块的潜力.

研究的目的:

为了评估静脉内MRI (IVMRI) 在分辨人体动脉的组成中的有效性.
为了比较IVMRI的性能与血管内超声波 (IVUS) 进行斑块表征.

主要方法:

对人类动脉样硬化动脉的ex vivo组织病理学进行IVMRI验证.
使用0.030英寸的IVMRI线圈与1.5T扫描仪获取T1,T2和质子密度加权图像.
这项技术在体内应用于25名人类受试者,结果与IVUS相比较.

主要成果:

IVMRI成功地分化了具有高灵敏度和特异性的脂质,纤维和化斑块成分.
IVMRI精确量化了斑块大小和可视化边界,即使在IVUS失败的化动脉中也是如此.
在解释斑块组成方面,IVMRI显示了观察者之间的和观察者内部的高度一致性,优于IVUS.

结论:

血管内MRI (IVMRI) 是确定深层动脉中的斑块组成和大小的可靠工具.
IVMRI在体内表征斑块的能力对推进动脉样硬化研究和治疗有重大影响.

更多相关视频

Cancer Vaccines

Cancer Vaccines

Development of Immunocompetence

Development of Immunocompetence

相关概念视频

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

Vaccinations

Vaccinations

Healthcare Associated Infections II: Preventive Measures

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...